Vir Biotechnology (VIR) Cash from Investing Activities (2018 - 2026)

Vir Biotechnology's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 90.67% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $195.4 million (down 67.31% YoY), while the FY2025 annual figure was $310.4 million, down 37.85% from the prior year.
• Cash from Investing Activities came in at $11.8 million for Q1 2026 at Vir Biotechnology, down from $86.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $230.3 million in Q2 2023 to a low of -$662.6 million in Q3 2022.
• A 5-year average of -$12.2 million and a median of $40.4 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities slumped 997.12% in 2022 and surged 346.23% in 2025, its largest moves.
• Vir Biotechnology's Cash from Investing Activities stood at -$153.1 million in 2022, then jumped by 31.56% to -$104.8 million in 2023, then surged by 234.28% to $140.7 million in 2024, then plunged by 38.43% to $86.7 million in 2025, then tumbled by 86.34% to $11.8 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $11.8 million, $86.7 million, and $40.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison